{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:18:46Z","timestamp":1784866726060,"version":"3.55.0"},"reference-count":44,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2020-02025"],"award-info":[{"award-number":["2020-02025"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["21 0313 SIA"],"award-info":[{"award-number":["21 0313 SIA"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Recent preclinical studies reported that the BCL-2 inhibitor venetoclax can impair bone growth. A strategy to prevent such a side effect of this promising anticancer drug is highly desired. Earlier in vitro and in vivo studies suggested that the mitochondrial peptide humanin has the potential to prevent drug-induced growth impairment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We hypothesized that co-treatment with the humanin analog HNG may prevent venetoclax-induced bone growth impairment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Ex vivo studies were performed in fetal rat metatarsal bones and human growth plate samples cultured for 12 and 2\u2005days, respectively, while in vivo studies were performed in young neuroblastoma mice being treated daily for 14\u2005days. The treatment groups included venetoclax, HNG, venetoclax plus HNG, or vehicle. Bone growth was continuously monitored and at the end point, histomorphometric and immunohistochemical analyses were performed in fixed tissues.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Venetoclax suppressed metatarsal bone growth and when combined with HNG, bone growth was rescued and all histological parameters affected by venetoclax monotherapy were normalized. Mechanistic studies showed that HNG downregulated the pro-apoptotic proteins Bax and p53 in cultured metatarsals and human growth plate tissues, respectively. The study in a neuroblastoma mouse model confirmed a growth-suppressive effect of venetoclax treatment. In this short-term in vivo study, no significant bone growth-rescuing effect could be verified when testing HNG at a single dose. We conclude that humanin dose-dependently protects ex vivo cultured metatarsal bones from venetoclax-induced bone growth impairment by restoring the growth plate microstructure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvae009","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T12:32:38Z","timestamp":1706099558000},"source":"Crossref","is-referenced-by-count":3,"title":["Humanin Treatment Protects Against Venetoclax-Induced Bone Growth Retardation in <i>Ex Vivo<\/i> Cultured Rat Bones"],"prefix":"10.1210","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3211-1664","authenticated-orcid":false,"given":"Lilly","family":"Velentza","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet , 171 65 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Wickstr\u00f6m","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet , 171 65 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Kogner","sequence":"additional","affiliation":[{"name":"Division of Pediatric Oncology and Surgery, Department of Women's and Children's Health, Karolinska Institutet , 171 65 Stockholm , Sweden"},{"name":"Astrid Lindgren Children's Hospital, Karolinska University Hospital , 171 64 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9633-2805","authenticated-orcid":false,"given":"Claes","family":"Ohlsson","sequence":"additional","affiliation":[{"name":"Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , 413 45 Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farasat","family":"Zaman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet , 171 65 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"S\u00e4vendahl","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology, Department of Women's and Children's Health, Karolinska Institutet , 171 65 Stockholm , Sweden"},{"name":"Astrid Lindgren Children's Hospital, Karolinska University Hospital , 171 64 Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"issue":"1","key":"2024021906212746900_bvae009-B1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc3634","article-title":"Survivors of childhood and adolescent cancer: life-long risks and responsibilities","volume":"14","author":"Robison","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2024021906212746900_bvae009-B2","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/MOP.0000000000000681","article-title":"Caring for survivors of childhood cancer: it takes a village","volume":"30","author":"Song","year":"2018","journal-title":"Curr Opin Pediatr"},{"issue":"8","key":"2024021906212746900_bvae009-B3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/jbmr.3447","article-title":"Bone morbidity and recovery in children with acute lymphoblastic leukemia: results of a six-year prospective cohort study","volume":"33","author":"Ward","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024021906212746900_bvae009-B4","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/ijc.33741","article-title":"Skeletal adverse events in childhood cancer survivors: an adult life after childhood cancer in Scandinavia cohort study","volume":"149","author":"Oskarsson","year":"2021","journal-title":"Int J Cancer"},{"issue":"4","key":"2024021906212746900_bvae009-B5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jpeds.2006.11.036","article-title":"Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study","volume":"150","author":"Chow","year":"2007","journal-title":"J Pediatr"},{"issue":"12","key":"2024021906212746900_bvae009-B6","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1210\/jc.2019-00834","article-title":"Hypothalamic\u2013pituitary disorders in childhood cancer survivors: prevalence, risk factors and long-term health outcomes","volume":"104","author":"van Iersel","year":"2019","journal-title":"The Journal of Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2024021906212746900_bvae009-B7","first-page":"80","article-title":"Effects of chemotherapy on bone metabolism and skeletal growth","volume":"58","author":"Siebler","year":"2002","journal-title":"Horm Res"},{"issue":"2","key":"2024021906212746900_bvae009-B8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/JOE-11-0048","article-title":"The skeleton: a multi-functional complex organ: the growth plate chondrocyte and endochondral ossification","volume":"211","author":"Mackie","year":"2011","journal-title":"J Endocrinol"},{"issue":"41","key":"2024021906212746900_bvae009-B9","doi-asserted-by":"crossref","first-page":"69295","DOI":"10.18632\/oncotarget.20619","article-title":"Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor","volume":"8","author":"Robinson","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"2024021906212746900_bvae009-B10","doi-asserted-by":"crossref","first-page":"e50523","DOI":"10.1371\/journal.pone.0050523","article-title":"Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice","volume":"7","author":"Eriksson","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"2024021906212746900_bvae009-B11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.bone.2007.07.021","article-title":"Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects","volume":"41","author":"Xian","year":"2007","journal-title":"Bone"},{"issue":"2","key":"2024021906212746900_bvae009-B12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/cbt.6.2.3576","article-title":"Effects of etoposide and cyclophosphamide acute chemotherapy on growth plate and metaphyseal bone in rats","volume":"6","author":"Xian","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2024021906212746900_bvae009-B13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1677\/joe.0.1760331","article-title":"Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes","volume":"176","author":"Chrysis","year":"2003","journal-title":"J Endocrinol"},{"issue":"1","key":"2024021906212746900_bvae009-B14","doi-asserted-by":"crossref","first-page":"8054","DOI":"10.1038\/s41598-023-34965-4","article-title":"Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth","volume":"13","author":"Velentza","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"2024021906212746900_bvae009-B15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/apa.15948","article-title":"The history, physiology and treatment safety of growth hormone","volume":"111","author":"Tidblad","year":"2022","journal-title":"Acta Paediatr"},{"issue":"3","key":"2024021906212746900_bvae009-B16","doi-asserted-by":"crossref","first-page":"djt459","DOI":"10.1093\/jnci\/djt459","article-title":"Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment","volume":"106","author":"Eriksson","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2024021906212746900_bvae009-B17","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1096\/fj.201801741R","article-title":"Humanin is a novel regulator of Hedgehog signaling and prevents glucocorticoid-induced bone growth impairment","volume":"33","author":"Zaman","year":"2019","journal-title":"FASEB J"},{"issue":"11","key":"2024021906212746900_bvae009-B18","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1073\/pnas.101133498","article-title":"A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta","volume":"98","author":"Hashimoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024021906212746900_bvae009-B19","doi-asserted-by":"crossref","first-page":"823354","DOI":"10.3389\/fcell.2022.823354","article-title":"The molecular structure and role of humanin in neural and skeletal diseases, and in tissue regeneration","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"2024021906212746900_bvae009-B20","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.18632\/aging.103534","article-title":"The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan","volume":"12","author":"Yen","year":"2020","journal-title":"Aging (Albany, NY)"},{"issue":"3","key":"2024021906212746900_bvae009-B21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.metabol.2009.08.001","article-title":"The neurosurvival factor humanin inhibits beta-cell apoptosis via signal transducer and activator of transcription 3 activation and delays and ameliorates diabetes in nonobese diabetic mice","volume":"59","author":"Hoang","year":"2010","journal-title":"Metab Clin Exp"},{"issue":"24","key":"2024021906212746900_bvae009-B22","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1016\/j.lfs.2005.03.031","article-title":"Involvement of tyrosine kinases and STAT3 in humanin-mediated neuroprotection","volume":"77","author":"Hashimoto","year":"2005","journal-title":"Life Sci"},{"issue":"22","key":"2024021906212746900_bvae009-B23","doi-asserted-by":"crossref","first-page":"13042","DOI":"10.1073\/pnas.2135111100","article-title":"Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis","volume":"100","author":"Ikonen","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024021906212746900_bvae009-B24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.brainres.2008.06.018","article-title":"Neuroprotective effect of humanin on cerebral ischemia\/reperfusion injury is mediated by a PI3K\/Akt pathway","volume":"1227","author":"Xu","year":"2008","journal-title":"Brain Res"},{"issue":"16","key":"2024021906212746900_bvae009-B25","doi-asserted-by":"crossref","first-page":"15815","DOI":"10.1074\/jbc.M411902200","article-title":"Humanin binds and nullifies Bid activity by blocking its activation of Bax and Bak","volume":"280","author":"Zhai","year":"2005","journal-title":"J Biol Chem"},{"issue":"11","key":"2024021906212746900_bvae009-B26","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1359\/JBMR.040805","article-title":"Interleukin-1beta and TNF-alpha act in synergy to inhibit longitudinal growth in fetal rat metatarsal bones","volume":"19","author":"M\u00e5rtensson","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021906212746900_bvae009-B27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.toxlet.2013.10.020","article-title":"Dexamethasone differentially regulates Bcl-2 family proteins in human proliferative chondrocytes: role of pro-apoptotic Bid","volume":"224","author":"Zaman","year":"2014","journal-title":"Toxicol Lett"},{"issue":"32","key":"2024021906212746900_bvae009-B28","doi-asserted-by":"crossref","first-page":"E6603","DOI":"10.1073\/pnas.1706011114","article-title":"Rho-associated kinase is a therapeutic target in neuroblastoma","volume":"114","author":"Dyberg","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024021906212746900_bvae009-B29","doi-asserted-by":"crossref","first-page":"13400","DOI":"10.1038\/s41598-020-69904-0","article-title":"Radial shock waves prevent growth retardation caused by the clinically used drug vismodegib in ex vivo cultured bones","volume":"10","author":"Ramesh","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"2024021906212746900_bvae009-B30","doi-asserted-by":"crossref","first-page":"18189","DOI":"10.1038\/s41598-022-22734-8","article-title":"Tnf overexpression and dexamethasone treatment impair chondrogenesis and bone growth in an additive manner","volume":"12","author":"Zhao","year":"2022","journal-title":"Sci Rep"},{"issue":"7","key":"2024021906212746900_bvae009-B31","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1172\/JCI6730","article-title":"Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-\/-) mice","volume":"104","author":"Windahl","year":"1999","journal-title":"J Clin Invest"},{"issue":"7","key":"2024021906212746900_bvae009-B32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1034\/j.1600-0714.2000.290706.x","article-title":"Establishment of a cell line with phenotypes of chondrocyte from a human osteogenic sarcoma of the mandible","volume":"29","author":"Yagami","year":"2000","journal-title":"J Oral Pathol Med"},{"key":"2024021906212746900_bvae009-B33","doi-asserted-by":"publisher","author":"Velentza","DOI":"10.6084\/m9.figshare.25048286.v1"},{"key":"2024021906212746900_bvae009-B34","first-page":"54978","article-title":"Culture of murine embryonic metatarsals: a physiological model of endochondral ossification","volume":"(118)","author":"Houston","year":"2016","journal-title":"J Vis Exp"},{"key":"2024021906212746900_bvae009-B35","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nature01627","article-title":"Humanin peptide suppresses apoptosis by interfering with Bax activation","volume":"423","author":"Guo","year":"2003","journal-title":"Nature"},{"issue":"50","key":"2024021906212746900_bvae009-B36","doi-asserted-by":"crossref","first-page":"19055","DOI":"10.1074\/jbc.RA119.011297","article-title":"Humanin induces conformational changes in the apoptosis regulator BAX and sequesters it into fibers, preventing mitochondrial outer-membrane permeabilization","volume":"294","author":"Morris","year":"2019","journal-title":"J Biol Chem"},{"key":"2024021906212746900_bvae009-B37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.yexmp.2019.104261","article-title":"The humanin analogue (HNG) prevents temozolomide-induced male germ cell apoptosis and other adverse effects in severe combined immuno-deficiency (SCID) mice bearing human medulloblastoma","volume":"109","author":"Jia","year":"2019","journal-title":"Exp Mol Pathol"},{"issue":"4","key":"2024021906212746900_bvae009-B38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10495-015-1105-5","article-title":"The effects of humanin and its analogues on male germ cell apoptosis induced by chemotherapeutic drugs","volume":"20","author":"Jia","year":"2015","journal-title":"Apoptosis"},{"issue":"6","key":"2024021906212746900_bvae009-B39","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"1","key":"2024021906212746900_bvae009-B40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1083\/jcb.200507106","article-title":"P53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling","volume":"172","author":"Wang","year":"2006","journal-title":"J Cell Biol"},{"issue":"20","key":"2024021906212746900_bvae009-B41","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.1158\/0008-5472.CAN-06-3982","article-title":"Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice","volume":"67","author":"Zaman","year":"2007","journal-title":"Cancer Res"},{"issue":"8","key":"2024021906212746900_bvae009-B42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1158\/1535-7163.MCT-20-0710","article-title":"Venetoclax-based rational combinations are effective in models of MYCN-amplified neuroblastoma","volume":"20","author":"Dalton","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2024021906212746900_bvae009-B43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1126\/scitranslmed.aao4680","article-title":"Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma","volume":"10","author":"Lochmann","year":"2018","journal-title":"Sci Transl Med"},{"issue":"3","key":"2024021906212746900_bvae009-B44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.molcel.2016.09.016","article-title":"Polo-like kinase-1 regulates Myc stabilization and activates a feedforward circuit promoting tumor cell survival","volume":"64","author":"Xiao","year":"2016","journal-title":"Mol Cell"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvae009\/56419530\/bvae009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/3\/bvae009\/56676084\/bvae009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/8\/3\/bvae009\/56676084\/bvae009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T06:21:56Z","timestamp":1708323716000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvae009\/7589533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1,16]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvae009","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,1,16]]},"article-number":"bvae009"}}